Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Recurrence 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Carcinoma, Transitional Cell 1Camurati-Engelmann Syndrome 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × ascrinvacumab × Clear all
NCT05178043 2024-02-22

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Unknown
5 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01486368 2023-08-04

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2 Completed
17 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

NCT01911273 2015-10-28

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Pfizer

Phase 2 Terminated
3 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡